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Purpose: The carbohydrate-binding protein Galectin-3 is increased in several inflammatory 
diseases and has recently been forwarded as a systemic biomarker in chronic obstructive 
pulmonary disease (COPD). In this longitudinal study, we characterized the level of systemic 
Galectin-3 using blood from smokers with a history of COPD and chronic bronchitis 
(COPD-CB), during stable clinical conditions and exacerbations.
Patients and Methods: The study population comprised 56 long-term smokers with 
COPD-CB, 10 long-term smokers without lung disease (LTS) and 10 clinically healthy 
never-smokers (HNS). Blood samples were analyzed for levels of Galectin-3, leukocyte 
populations and C-reactive protein (CRP). In addition, sputum samples from the COPD- 
CB group were analyzed for bacterial growth.
Results: When comparing stable clinical conditions and exacerbations in the COPD-CB 
group, we found that the level of Galectin-3, just like that of CRP, leukocytes and neutrophils, 
respectively, was increased during exacerbations. However, this exacerbation-associated 
increase of Galectin-3 was modest. During stable clinical conditions of COPD-CB, the level 
of Galectin-3 was not elevated in comparison with HNS or LTS. Nor did this level of Galectin- 
3 distinguish patients that remained in a clinically stable condition throughout the study to 
those that developed an exacerbation. In addition, neither during stable clinical conditions nor 
during exacerbations, did the presence of bacterial growth in sputum alter Galectin-3 levels. In 
contrast to Galectin-3, the level of CRP, leukocytes and neutrophils, respectively, were 
increased during clinical stable conditions in the COPD-CB group compared with the other 
groups and were further enhanced during exacerbations.
Conclusion: Systemic Galectin-3 is increased in a reproducible but modest manner during 
exacerbations in smokers with COPD-CB. During stable clinical conditions, the level of 
systemic Galectin-3 does not distinguish patients that remain clinically stable from those that 
develop exacerbations. This makes it less likely that systemic Galectin-3 may become 
a clinically useful biomarker in the current setting.
Keywords: COPD, CRP, airflow limitation, exacerbation
Introduction
Chronic obstructive pulmonary disease (COPD) is a burden to public health and a global 
killer, projected to soon become the third leading cause of disease-related death 
worldwide.1 According to the Global initiative for Chronic Obstructive Lung Disease 
(GOLD), COPD is characterized by persistent airflow limitation associated with a chronic 
inflammatory response that is caused by long-term exposure to noxious gases and/or toxic 
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particles.2 The persistent airflow limitation is primarily caused 
by bronchiolitis that causes irreversible obstruction but it may 
be enhanced by parenchymal destruction (emphysema) and 
excessive mucus production (chronic bronchitis). Many 
patients with COPD suffer from repeated episodes of severely 
increased symptoms (exacerbations), characterized by even 
more pronounced local and systemic inflammation, leading 
to the transient deterioration of lung function, reduced quality 
of life, hospitalization, and risk for further disease 
progression.2 In the Western world, the most common cause 
of COPD is smoke from tobacco but smoke from other types of 
biomass may also increase the risk for COPD.3–5
From a clinical point-of-view, it seems critical to pre-
vent exacerbations of COPD, in order to preserve lung 
function, for the sake of the patient and for the sake of 
the health economy.3 However, despite substantial 
research efforts to identify biomarkers in blood that can 
predict exacerbations,2,6–13 none have so far proven prac-
tically useful in the clinical setting for the general assess-
ment of exacerbations in individual patients.
Galectin-3 (Mac-2) is a β-galactoside-binding protein pro-
duced by various tissues and cell types in humans,14–16 includ-
ing monocytes and, even more so, macrophages.17 This is 
noteworthy given that the number of alveolar macrophages is 
enhanced in COPD.18,19 Interestingly, Galectin-3 has been 
implied as a key regulator of innate immunity,20 due to its 
ability to enhance phagocytosis,21–23 initiate the production of 
reactive oxygen species24,25 and promote cell adhesion.26,27 
With reference to clinical pathology, previous studies have 
demonstrated enhanced systemic levels of Galectin-3 in 
patients with various types of cancer28–30 and heart 
failure,31,32 respectively. In terms of airway disease, one 
study has demonstrated an increased level of Galectin-3 locally 
in the airways during stable clinical conditions for very severe 
COPD and chronic bronchitis (CB), with all investigated 
patients being former smokers.33 Another study demonstrated 
that the systemic level of Galectin-3 in the blood is increased 
during exacerbations in patients with moderate to severe 
COPD.34 However, the described enhancement of Galectin-3 
emerged as modest, possibly due to different confounders like 
the variation in pharmacotherapy and the exact timing of 
sampling. Additional confounders were evident as well, since 
the patients with COPD comprised both never-, ex- and cur-
rent-smokers and it was unclear whether they suffered from 
CB.34 The latter might be important since CB is a comorbidity 
that increases the risk for exacerbations.35
In the present study, we assessed systemic levels of 
Galectin-3 by sampling blood before and during exacerbations 
in patients with a confirmed history of COPD and CB (COPD- 
CB). We compared these systemic levels of Galectin-3 to 
those in matching samples collected from clinically healthy 
never-smokers (HNS) and to those in samples from long-term 
smokers (LTS) with normal lung function/spirometry and 
without COPD-CB. Notably, we confirmed a consistent status 
of current smoking among all included LTS and COPD-CB 
patients, by assessing the nicotine metabolite cotinine. Finally, 
we related Galectin-3 in the blood to the archetype marker of 
systemic inflammation in the blood, C-reactive protein (CRP), 
and to the detection of local bacterial pathogens in airway 
samples from the COPD-CB patients.
Patients and Methods
Study Population
The study subjects were recruited by advertisement in the 
newspaper or from the outpatient clinic at the Department of 
Respiratory Medicine at Sahlgrenska Hospital in Gothenburg, 
Sweden. The main study group included 56 long-term smo-
kers (>10 pack-years) who were all current smokers (positive 
for cotinine) with a confirmed COPD diagnosis (Table 1). 
Among these 56 patients, 53 patients (95%) had a COPD 
diagnosis in their patient records prior to screening and three 
received the diagnosis during screening.36,37 For all these 
patients, the diagnosis of COPD was set by experienced 
clinicians.2 Thus, all included patients displayed spirometry 
results with an FEV1/FVC ratio (%) of less than 70% and 
GOLD-staging was performed based upon FEV1 (% 
predicted).38 The diagnosis “chronic bronchitis” was set after 
confirmation that the patient had a productive cough during at 
least 3 months per year for two subsequent years, in accor-
dance with the classic criteria by Kim et al.39
During the inclusion visit, we ascertained that all patients 
had been without clinical signs of infections during the four 
most recent weeks prior to inclusion. Other than CB, 43 out of 
the 56 patients (77%) suffered from comorbidities including 
osteoporosis, hypertension, diabetes and depression (Table 2), 
which are common amongst patients with COPD.40 The 
exclusion criteria in this COPD-CB group were as follows: i) 
long-term oxygen therapy, ii) regular use of oral glucocorti-
coids, iii) any additional lung disease other than COPD or CB 
(eg, pulmonary fibrosis, asbestosis, alpha-1 antitrypsin defi-
ciency or sarcoidosis), iv) allergy, sensitization or asthma or v) 
other serious diseases (including congestive heart failure and 
ischemic heart disease, mental illness [apart from depression], 
malignancies and chronic inflammatory diseases such as rheu-
matoid arthritis and inflammatory bowel disease).
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Two control groups were also recruited as follows: ten 
clinically healthy never-smokers (HNS; negative for coti-
nine) and ten long-term smokers (LTS) who were all 
current smokers (positive cotinine) but had normal lung 
function/spirometry. The latter group had no chronic bron-
chitis or other lung diseases, as judged from their history. 
The clinical characteristics of all study subjects/patients 
are summarized in Table 1. Of note, the original study 
population has been described in two previous publica-
tions, focusing on primary outcomes other than Galectin- 
3.36,37 Thus, beyond Galectin-3, certain clinical and 
laboratory data from the included study subjects have 
previously been utilized in a different scientific context.
Study Protocol
Briefly, before inclusion, all subjects were examined dur-
ing stable clinical conditions and critically evaluated 
regarding the results of physical examination, lung func-
tion tests (spirometry, gas diffusion capacity), chest X-ray, 
and sputum, urine and blood samples, as previously 
described.37 Both blood and sputum samples (study mate-
rial) were collected from the patients at the time of inclu-
sion and blood samples were thereafter collected every 
15th week during the following 60 weeks. If the patient 
experienced signs of an exacerbation, an extra visit was 
scheduled for the collection of blood and sputum samples, 
with the aim to obtain samples prior to any emergency 
medication was given because of the exacerbation.
Bacteria in Sputum Samples
Fresh sputum samples were collected from the COPD-CB 
group at the time of inclusion and during exacerbations. To 
assess whether the sputum samples were representative for 
the lower airways, all samples were evaluated for cell 
morphology before utilized for the culture of bacteria as 
previously described.36,37
Cotinine
Fresh urine samples collected at the time of inclusion were 
analyzed for cotinine, the major metabolite of nicotine. 
This analysis was performed using a visual one-step 
immunoassay for the qualitative detection of cotinine 
(One-Step Cotinine TestTM #008A086, Ulti Med 
Products, Ahrensburg, Germany), with a cut-off concen-
tration of 200 ng/mL, according to manufacturer’s 
instructions.
Table 1 Clinical Characteristics of Study Subjects at Inclusiona
HNS LTS COPD-CB
n 10 10 56
Sex (Male/Female) 3/7 2/8 23/33
Age (years) 68 (47–70) 50 (26–64)*(†,§) 63 (45–76)
Pack-years (range) 0 (0) 28 (13–43) 40 (14–156)
BMI (kg/m2) 25 (20–31) 26 (22–31) 26 (17–34)
FEV1 (% of predicted) 120 (97–137) 106 (83–119) 60 (29–97)*
(†,‡)
FEV1/FVC (FEV%) 79 (73–84) 77 (73–84) 55 (28–68)*
(†,‡)
DLCO (% of predicted) 98 (75–139) 87 (77–111) 70 (44–110)*(†,‡)
CRP (mg/L) 0.8 (0.2–5.7) 0.7 (0.2–5.8) 1.7 (0.3–15.0)*(†)
Leukocytes (x 109/L) 5.0 (4.0–7.6) 7.5 (4.2–12.5) 7.5 (3.9–14.6)*(†)
Medications (n)b
Untreated – – 4
Bronchodilator – – 44
Glucocorticoid – – 8
Combination – – 23
Mucolytics – – 18
Notes: Data is given as median (range minimum-maximum value) based on the total n in each group (HNS, n=10; LTS, n=10; COPD-CB, n=56) except for: pack-years, 
include nine LTS individuals; DLCO, include 54 COPD-CB patients; CRP, include 55 COPD-CB patients. 
Statistical analysis: Mann–Whitney U test showed no statistical significant difference in pack-years between LTS and COPD-CB patients (p = 0.057); Kruskal–Wallis test 
followed by Dunn’s multiple comparison test revealed statistical significant lower age in LTS compared to both HNS (†) and COPD-CB patients (§), statistical significant lower 
FEV1, FEV1/FVC and DLCO values in the COPD-CB patients compared to both HNS and LTS (
‡) and statistical significant higher CRP and leukocytes levels in the COPD-CB 
patients compared HNS (†). No statistical significant differences were found for BMI. Statistically significant differences are indicated as follows: (*) p-value <0.05. aSome 
parameters have been described in our previous publications.36,37 bAll medications were administered by inhalation, except mucolytics (N-acetylcysteine, oral intake). 
Bronchodilator include short- and long-acting anticholinergics and β2-agonists and combination include inhalers with a bronchodilator and a glucocorticoid. 
Abbreviations: BMI, body mass index; CRP, C-reactive protein; DLCO, gas diffusion capacity for carbon monoxide; FEV1, forced expiratory volume in one second; FVC, 
forced vital capacity; HNS, healthy never smokers; LTS, long-term smokers without chronic obstructive pulmonary disease and chronic bronchitis (COPD-CB).
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Galectin-3
Fresh blood samples were processed to obtain serum and 
were then frozen (−80°C). After thawing, Galectin-3 protein 
was quantified utilizing a commercial enzyme-linked immu-
nosorbent assay (ELISA) on a microtiter platform with 
a measurement range of 1.4–94.8 ng/mL (BGM Galectin-3 
Assay #12836, BG Medicine, Inc. Waltham, MA, USA), in 
accordance with the manufacturer’s instructions.
C-Reactive Protein (CRP)
The level of CRP was assessed in serum samples utilizing 
a particle-enhanced immunoturbidimetric assay in which 
human CRP agglutinate with latex particles coated with 
anti-CRP antibodies (Tina-quant C-reactive protein high- 
sensitive assayTM HS No 1972944001; Hoffmann-La 
Roche Ltd, Basel, Switzerland) at the Department of 
Clinical Chemistry, Sahlgrenska University Hospital, 
Gothenburg, Sweden, in accordance with the manufac-
turer’s instructions.
Leukocytes
The level (absolute concentration) of all (total) leukocytes and 
the respective subpopulation was quantified by hematology 
analysis (ADVIA 2120i Hematology systemTM; Siemens, 
Duisburg, Germany) at the Department of Clinical 
Chemistry, Sahlgrenska University Hospital, Gothenburg, 
Sweden, in accordance with the manufacturer’s instructions.
Statistical Analysis
Non-parametric statistical analyses were performed in 
Graph Pad Prism version 8.3.1 (GraphPad Software, San 
Diego, CA, USA) using a Mann–Whitney U test, 
Wilcoxon signed-rank test or Kruskal–Wallis test followed 
by Dunn’s multiple to evaluate differences between groups 
or Spearman’s rank correlation to evaluate correlations 
between Galectin-3 and CRP or leukocytes during exacer-
bations. The specific statistical tests applied are presented 
in the respective figure legend and table footnotes. 
A p-value of <0.05 was regarded as statistically significant 
and the p-value was indicated as follows: *) p<0.05; **) 
p<0.01; ***) p<0.001 and ****) p<0.0001.
Results
Characteristics of the Study Population
The clinical characteristics of the COPD-CB group and control 
groups (HNS and LTS) are described in Table 1. The spiro-
metric parameters measured (FEV1, FEV1/FVC and DLCO) 
were all altered in a statistically significant and typical manner 
in the COPD-CB group as compared to both control groups. 
However, the historic tobacco load (number of pack-years) did 
not markedly differ between the COPD-CB and LTS group. In 
52 (93%) of the patients in the COPD-CB group, inhalation 
(bronchodilators and/or glucocorticoids) and/or orally admi-
nistered mucolytics were utilized by the patients during stable 
clinical conditions (Table 1). The patients in the COPD-CB 
group displayed severity corresponding to GOLD stage I, II, 
III and IV.38 As assessed by a questionnaire, 43 (77%) of the 
patients in the COPD-CB group recalled having exacerbations 
the last year preceding inclusion in the study. Throughout the 
study, 34 (61%) of the 56 patients in the COPD-CB group 
suffered from exacerbations (Table 2).
Galectin-3 During Stable Clinical 
Conditions
During the stable clinical conditions at the time of inclu-
sion, the (median) level of Galectin-3 in serum was similar 
Table 2 Exacerbation Frequency and Comorbidities
Disease Severitya Mild Severe
n 39 17
Exacerbations prior study (n)b
Do not recall 10 3
0 5 3
1–2 19 7
≥ 3 5 4








Cardiac diseasec 3 1
Osteoporosis/Osteopenia 7 3
Hypercholesterolemia 8 1
Type 2 diabetes mellitus 3 –
Hypothyroidism 5 –
Sleep apnea 1 –
Depression/anxiety 14 4
Notes: aThe COPD-CB patients were classified according to the Global initiative 
for Chronic Obstructive Lung Disease (GOLD) criteria as of 201138; mild, COPD- 
CB corresponding to GOLD stage I and II; severe, COPD-CB corresponding to 
GOLD stage III and IV. bBased on the year prior study inclusion and estimated by 
a questionnaire consisting of five domains: number of exacerbations: 0; 1–2; 3; >3 
or, do not recall/unsure. cCardiac disease includes atrial flutter, mechanical valve 
surgery, silent myocardial infarction and sinus tachycardia.
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for the COPD-CB and the HNS and LTS control group, 
respectively (Figure 1A).
We also evaluated whether the level of Galectin-3 
during stable clinical conditions (at the time of inclusion) 
predicts an upcoming exacerbation in the COPD-CB 
group. We did this by comparing the level for the 22 
(39%) patients that remained in a clinically stable condi-
tion throughout the study, with that of the 34 (61%) that 
developed an exacerbation during the study. However, we 
detected no substantial difference in the level of Galectin-3 
during stable clinical conditions for these two sub-groups 
(Figure 1B). In addition, we analyzed if the level of 
Galectin-3 during stable clinical conditions (at the time 
of inclusion) correlated with the number of exacerbations 
in the patients from the COPD-CB group that experienced 
this condition during the study. However, there was no 
statistically significant correlation in this respect 
(Spearman’s Rho = −0.15, 95% confidence interval −0.-
40–0.13, number of exacerbations are shown in Table 2).
For comparison to Galectin-3, we also determined the 
level of the acute phase reactant CRP.5,41–43 Here, the level of 
CRP was increased in the COPD-CB group at the time of 
inclusion, as compared to the HNS and LTS control group, 
respectively. However, just like the case for Galectin-3, the 
level of CRP was not markedly different for the COPD-CB 
patients with and without exacerbations, respectively 
(Figure 1C).
Galectin-3 During Exacerbations
Galectin-3 in serum was also quantified in 29 (85%) of the 34 
patients in the COPD-CB group that suffered from exacerba-
tions during the 15-month course of the study. For all these 29 
patients, blood and sputum samples were collected prior to the 
administration of emergency medication. By comparing the 
level of Galectin-3 at the last regular visit prior to the exacer-
bation (during stable clinical conditions) with that obtained 
during the exacerbation, a statistically significant increase in 
the level of Galectin-3 was detected (Figure 2A). Here, the 
median (range) time from a prior visit to exacerbation was 12.5 
(2.7–15.5) weeks. Similar to Galectin-3, CRP displayed an 
increased level during an exacerbation, as compared to the 
most recent regular visit prior to the exacerbation (Figure 2B).
Galectin-3 in Relation to Bacteria in 
Sputum Samples
We also evaluated whether the level of Galetin-3 in the 
COPD-CB group was different for the patients with the 
growth of oropharyngeal flora, common respiratory patho-
gens or opportunistic pathogens. However, we detected no 
reproducible difference for these sub-groups, neither dur-
ing stable clinical conditions (at the time of inclusion) nor 
during exacerbations (Figure 3A and B).
Leukocytes During Exacerbations
We compared the levels (absolute concentration) of total 
leukocytes, as well as the subpopulations, monocytes and 
neutrophils, in blood from the COPD-CB group in samples 
obtained at the most recent visit prior to the exacerbation 
(during stable clinical conditions) to the one obtained 
during exacerbations. Here, we detected a statistically sig-
nificant increase in the level of total leukocytes and neu-
trophils during exacerbations (Figure 4A and B). For 
monocytes, there was a trend towards a similar increase 
(Figure 4C).
Figure 1 Serum levels of Galectin-3 during stable clinical conditions. (A) The level of Galectin-3 in serum from healthy never smoker (HNS; n=10, light grey dots) as well as 
from long-term smokers without (LTS; n=10, dark grey dots) and with chronic obstructive pulmonary disease and chronic bronchitis during stable clinical conditions at the 
time inclusion (COPD-CB inclusion; n=56, white dots). (B) The level of Galectin-3 and (C) the level of CRP in serum from COPD-CB patients at the time of inclusion that 
either remained in a stable clinical phase (remained stable; n=22 for both Galectin-3 and CRP) or developed an exacerbation (developed EXA; n=34 for Galectin-3, n=33 for 
CRP) during the course of the study. The data is presented as individual dots and median (bold line). Statistical analysis was performed using (A) a Kruskal–Wallis test 
followed by Dunn’s multiple comparison test or (B–C) a Mann–Whitney U test.
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Figure 2 Serum levels of Galectin-3 during exacerbations. The levels of (A) Galectin-3 (n=29) and (B) CRP (n=34) were measured in serum within each patient with chronic 
obstructive pulmonary disease and chronic bronchitis (COPD-CB) during stable clinical conditions at the most recent visit prior to an exacerbation (pre-EXA; white 
squares) and during the exacerbation (EXA; grey squares). Certain patients suffered from an exacerbation within the first 15 weeks of the 15 months’ course of the study, 
hence the inclusion sample constitute 11 of the 29 pre-EXA samples in (A) and 14 of the 34 pre-EXA samples in (B). The data is presented as individual dots and median 
(bold line). Statistical analysis was performed using Wilcoxon signed-rank test. Statistically significant differences are indicated as follows: *p-value <0.05; ***p-value <0.001.
Figure 3 Serum levels of Galectin-3 in relation to bacterial growth in sputum samples. Sputum samples were obtained from patients with chronic obstructive pulmonary 
disease and chronic bronchitis (COPD-CB) during (A) stable clinical conditions at the time of inclusion (n=36, white dots) and (B) and during exacerbation (EXA; n=19, grey 
squares) and the data show the level of Galectin-3 in serum in relation to the type of bacterial growth of oropharyngeal flora (inclusion, n=18, EXA n=7), common 
respiratory pathogens (inclusion, n=14, EXA n=12), and opportunistic pathogens (inclusion, n=4). The data is presented as individual dots and median (bold line). Statistical 
analysis was performed using (A), a Kruskal–Wallis test followed by Dunn’s multiple comparison test or (B), a Mann–Whitney U test.
Figure 4 Alterations in total white blood cells and neutrophils during exacerbations. The absolute counts (x109/L) of (A) leukocytes, (B) neutrophils and (C) monocytes 
were analyzed in blood from the same patients with chronic obstructive pulmonary disease and chronic bronchitis (COPD-CB) during stable clinical conditions at the most 
recent visit prior to an exacerbation (pre-EXA; n=34, white squares) and during the exacerbation (EXA; n=34, grey squares). Certain patients suffered from an exacerbation 
within the first 15 weeks of the 15 months’ course of the study, hence the inclusion sample constitute 14 of the 34 pre-EXA samples in (A–C). The data is presented as 
individual dots and median (bold line). Statistical analysis was performed using Wilcoxon signed-rank test. Statistically significant differences are indicated as follows: **p-value 
<0.01; ***p-value <0.001.
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Galectin-3 in Relation to CRP and 
Leukocytes During Exacerbations
We observed no correlation between the levels of Galectin-3 
and CRP during exacerbations, even though the level of both 
these proteins increased during these events (Figure 5A). We 
next examined if the increased level of Galectin-3 correlated 
with the increased level of total leukocytes, neutrophils or 
monocytes during exacerbations. However, no statistically 
significant correlation was detected (Figure 5B–D).
Discussion
In this longitudinal study, we characterized the level of 
Galectin-3 protein in serum samples from well- 
characterized patients with a history of COPD and CB and 
a confirmed status of current as well as historic smoking. Our 
results disclose that there is a reproducible but modest 
increase in the systemic levels of Galectin-3 during 
exacerbations. By optimizing the timing of sample collection 
during exacerbations, we avoided the confounding influence 
of emergency medication. Moreover, we investigated smo-
kers with COPD-CB, being prone to exacerbations,35 and we 
ascertained that all of these patients were current smokers. In 
contrast, in the preceding study on systemic Galectin-3 by 
Feng et al patients with COPD were investigated without 
information about CB, with inconsistent smoking status and 
uncertainties regarding sampling in relation to emergency 
medication.34 However, despite these differences in design, 
the study by Feng et al and our study show results along the 
same line, making it likely that systemic Galectin-3 is not 
very sensitive to common therapy against exacerbations.
We found that the average level of Galectin-3 in serum 
from the group of COPD-CB patients was indeed quite 
similar to the level in the HNS and LTS control group 
during stable clinical conditions. Indeed, our findings are 
Figure 5 Galectin-3 versus CRP, white blood cells, neutrophils and monocytes during exacerbations. Correlations between the level of (A) CRP (measured in serum), and 
absolute counts of (B) leukocytes, (C) neutrophils and (D) monocytes (measured in blood) and the level of Galectin-3 (measured in serum) from patients with chronic 
obstructive pulmonary disease and chronic bronchitis (COPD-CB) during exacerbations (n=29). Statistical analysis was performed using Spearman’s rank correlation (the 
rho- and p-values are shown in each figure).
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corroborated by those in a previous study on plasma levels 
of Galectin-3 in patients with severe COPD without 
a diagnosis of CB, and inconsistent smoking status, in 
comparison with healthy controls.44 Interestingly, a study 
on the local level of Galectin-3, assessed in bronchoalveo-
lar lavage fluid, suggests a decrease in COPD patients 
compared to healthy controls during clinical stable condi-
tions, suggesting a compartmental difference for systemic 
and local Galectin-3.45 Moreover, our current observations 
were made despite the detection of bacterial pathogens in 
certain patients with COPD and CB; the presence of bac-
teria was not associated with increased Galectin-3 neither 
during exacerbations nor during stable clinical conditions. 
Tentatively, it seems as if local bacteria in the airways do 
not markedly alter systemic levels of Galectin-3 in smo-
kers with COPD and CB.
We included measurements of CRP in serum as a reference 
biomarker in the current study, since this protein is regarded as 
a “golden standard” to assess systemic inflammation in 
patients with COPD.3,46 We found that CRP was clearly and 
reproducibly increased during exacerbations but this increase 
was modest; thereby confirming previous studies and suggest-
ing a limited practical utility of CRP as a general biomarker for 
the exacerbation per se in the individual patient. In this respect, 
the scope of our current study is very different from that of the 
study from Butler et al, who examined and proved the utility of 
CRP as a tool for rational prescription of antibiotics to COPD 
patients with exacerbations.13 Because of the exacerbation- 
related association of CRP and Galectin-3 that we observed, 
we investigated whether these two outcomes correlated but 
they did not. Possibly, this relates to that CRP and Galectin-3 
have different cellular origins and release mechanisms. Along 
these lines, even though CRP may be synthesized by several 
cell types, the main bulk of CRP is produced by hepatocytes,47 
whereas the main expression of Galectin-3 relates to myeloid 
cells.15,48 Such differences may explain why CRP displayed 
a consistent increase in smokers with COPD and CB even 
during stable clinical conditions37 whereas Galectin-3 in the 
same group was similar to that in LTS and HNS.
We compared the level of Galectin-3 in serum during 
stable clinical conditions in patients with COPD and CB 
who developed exacerbations with those who did not. 
Notably, this comparison did not indicate any clear differ-
ence and the level of Galectin-3 in serum during stable 
clinical conditions did not correlate with the number of 
exacerbations. Thus, although the sample size was moder-
ate and there is a certain risk for type II error, it is fair to 
state that our study failed to generate evidence in favor of 
Galectin-3 possessing potential as a predictive biomarker 
for future exacerbations.
The included patients with COPD and CB had a record 
of historic exacerbations and displayed characteristic signs 
of systemic inflammation during exacerbations, beyond the 
enhanced CRP level. These signs included enhanced total 
levels of leukocytes including neutrophils, as previously 
reported.37 Moreover, the included patients had 
a substantial tobacco load and the severity of COPD ranged 
from stage I to IV as defined by GOLD in 2011.38 Our 
current study material was larger than that investigated by 
Feng et al and, just like these authors, we excluded patients 
treated with oral or intravenous glucocorticoids, to avoid 
iatrogenic impact on immunological outcomes. Given these 
facts, we think that our study material is at least as relevant 
and representative as that studied by Feng et al.34
With reference to comorbidities other than chronic 
bronchitis, hypertension, osteoporosis, diabetes, hypothyr-
oidism, sleep apnea, depression and anxiety, we inter-
viewed the study subjects, checked their medical records, 
performed chest X-ray and tested lung function to exclude 
lung disease other than COPD-CB. With this approach, we 
also excluded severe congestive heart failure, ischemic 
heart disease, chronic inflammatory disease and malignan-
cies. In a similar manner, Feng et al interviewed the study 
subjects, checked their medical records, performed chest 
X-ray and tested lung function to exclude lung disease 
other than COPD-CB as well as ischemic heart disease, 
diabetes, autoimmune disease, chronic kidney disease and 
malignancies.34 Thus, in terms of the potentially con-
founding influence of comorbidities, this influence is likely 
to be modest in our study and in that by Feng et al.34
The actual levels (concentrations) of Galectin-3 protein 
detected in our current study cannot strictly be compared 
with those reported by Feng et al.34 This is because the 
referred authors utilized an ELISA to quantify Galectin-3 
that was different from the one we utilized. However, it is 
interesting to note that the average increase during exacerba-
tions was of a similar magnitude in both studies (~10% of the 
level during stable clinical conditions). Notably, the ELISA 
that we utilized has previously been used to quantify the level 
of Galectin-3 in a population of healthy humans encompass-
ing more than one thousand subjects.49,50 The median level 
was then 10.9 ng/mL (interquartile range [IQR] 9.0–13.1 ng/ 
mL)50 whereas it was 13.5 ng/mL (IQR 10.9–15.7 ng/mL) 
during stable clinical conditions in our current study. In other 
words, the levels of Galectin-3 in the COPD-CB patients that 
we investigated are quite similar to those previously detected 
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                            
International Journal of Chronic Obstructive Pulmonary Disease 2021:16 374


















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
in healthy subjects, presumably because patients with severe 
comorbidities were excluded.49,50
Conclusions
Our longitudinal study on long-term smokers with a history of 
COPD and CB demonstrates a reproducible increase in the 
level of Galectin-3 in serum during exacerbations. However, 
the modest magnitude of this increase makes it less likely that 
systemic Galectin-3 will be clinically useful as a biomarker for 
exacerbations in this setting. Moreover, our study failed to 
provide evidence that Galectin-3 in serum distinguishes the 
patients who are prone to exacerbations from those who are 
not. Furthermore, our study indicates that the level of Galectin- 
3 in serum during stable clinical conditions is quite similar to 
that in LTS or HNS, suggesting that systemic Galectin-3 is not 
pathogenically involved under these conditions in patients with 
COPD-CB. Although these results argue against Galectin-3 as 
a useful biomarker in these patients, the potential clinical utility 
of targeting systemic Galectin-3 for detecting cardiovascular 
comorbidities remains to be addressed in this setting.
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